Merck provided earnings guidance for the year 2022 and 2025. The company expects the 2021 momentum to continue both into the fourth quarter and into 2022, where they do expect another year of very strong growth. As they look out longer term, that momentum continues.

They expect continued strong revenue growth through 2025, driven largely by their derisked portfolio of growth assets.